Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: B

Drug products: Bensylpenicillin® Meda, BENZETACIL 1.200.000, Benzylpenicillin Panpharma, Bicillin C-R 900/300, Lentocilin S 1200, Pendysin, PFIZERPEN, Tardocillin, Tardocillin 1200

ATC code: J01CE01, J01CE08, J01CR50

Substances: benzylpenicillin, benzylpenicillin potassium, benzylpenicillin sodium, benzylpenicillin, procaine


Controlled studies on differences between men and women regarding safety and pharmacokinetics of benzylpenicillin are lacking. A cohort study has shown an higher serological cure of syphilis in men than in women following treatment with benzylpenicillin.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of benzylpenicillin have been found.


A register-based cohort study including 1327 patients with syphilis (782 men, 545 women) showed higher serological cure in men than in women, following treatment with benzylpenicillin [1].

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of benzylpenicillin have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2021-02-12

Date of litterature search: 2021-01-11


  1. Tong ML, Lin LR, Liu GL, Zhang HL, Zeng YL, Zheng WH et al. Factors associated with serological cure and the serofast state of HIV-negative patients with primary, secondary, latent, and tertiary syphilis. PLoS One. 2013;8(7):e70102. PubMed
  2. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Diana Rydberg

Approved by: Karin Schenck-Gustafsson